Interv Akut Kardiol. 2016;15(4):187-190 | DOI: 10.36290/kar.2016.037

Feochromocytom jako neobvyklá příčina refrakterní fibrilace komor

Pavel Hajdusek, Michal Pazdernik, Jiri Kettner, Josef Kautzner
Cardiology Department, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic

Feochromocytom je vzácný neuroendokrinní nádor s výrazně variabilní klinickou manifestací a záchvatovitým průběhem. Prevalence

feochomocytomu je velmi nízká a udává se přibližně u 0,1–0,6 % všech hypertoniků. Navzdory vzácnému výskytu hraje včasné

stanovení diagnózy zásadní roli v další léčbě. Ta může být v některých případech životně důležitá. Typickou klinickou manifestací

feochromocytomu je triáda bolestí hlavy, palpitací a zvýšeného pocení. Setrvalé komorové arytmie jsou popisovány vzácně. Přinášíme

popis neobvyklého případu feochromocytomu manifestujícího se refrakterní komorovou fibrilací, která vyžadovala protrahovanou

kardiopulmonální resuscitaci. Cílem této kazuistiky je ukázat záludnosti diagnosticko-terapeutického postupu a upozornit na vhodnost

komplexního vyšetření ve specializovaném kardiovaskulárním centru u všech pacientů přeživších srdeční zástavu.

Keywords: feochromocytom, refrakterní fibrilace komor, implantabilní kardioverter-defibrilátor

Published: December 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hajdusek P, Pazdernik M, Kettner J, Kautzner J. Feochromocytom jako neobvyklá příčina refrakterní fibrilace komor. Interv Akut Kardiol. 2016;15(4):187-190. doi: 10.36290/kar.2016.037.
Download citation

References

  1. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015; 36: 2793-2867. Go to original source...
  2. Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein Ds. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001; 134: 315-329. Go to original source...
  3. Maloberti A, Meani P, Pirola R, Varrenti M, Bionardi M, De Biase AM, Vallerio P, Bonacina E, Mancia G, Loli P, Giannattasio C. Acute coronary syndrome: a rare case of multiple endocrine neoplasia syndromes with pheochromocytoma and medullary thyroid carcinoma. Cancer Biol Med 2015; 12: 255-258.
  4. Galetta F, Franzoni F, Bernini G, Poupak F, Carpi A, Cini G, Tocchini L, Antonelli A, Santaro G. Cardiovascular complications in patients with pheochromocytoma: a mini-review. Biomed Pharmacother 2010; 64: 505-509. Go to original source...
  5. Magalhaes AP, Pastor A, Nú?ez A, Cosío FG. Ventricular Tachycardia as Initial Presentation of Pheochromocytoma, Rev Esp Cardiol 2007; 60: 450-451. Go to original source...
  6. Delekta J, Riahi S, Eschen O. Rare cause of ventricular tachycardia: Pheochromocytoma. J Cardiol Cases 2015; 11: 62-65. Go to original source...
  7. Cheng KH, Chu CS, Lai WT. Ventricular Tachycardia and Spontaneous Rupture of an Extra-adrenal Pheochromocytoma Case. Kaohsiung J Med Sci 2005; 21: 245-247. Go to original source...
  8. Zelinka T, Petrak O, Turkova H, et al. High incidence of cardiovascular complications in pheochromocytoma. Horm Metab Res 2012; 44: 379-384. Go to original source... Go to PubMed...
  9. Yu R, Nissen NN, Bannykh SI. Cardiac complications as initial manifestation of pheochromocytoma: frequency, outcome, and predictors. Endocr Pract 2012; 18: 483-492. Go to original source... Go to PubMed...
  10. Verzeletti A, Amariti ML. Sudden death from an asymptomatic phaeochromocytoma, J Forensic Leg Med 2011;18:180-181. Go to original source...
  11. Sawka AM, Jaeschke R, Singh RJ, Young WF Jr. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 2003; 88: 553-558. Go to original source...
  12. Pappachan JM, Raskauskiene D, Sriraman R, Edavalath M, Hanna FW. Diagnosis and management of pheochromocytoma: a practical guide to clinicians. Curr Hypertens Rep 2014; 16: 442. Go to original source... Go to PubMed...
  13. Kudva YC, Sawka AM, Young WF Jr. Clinical review 164: The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. J Clin Endocrinol Metab 2003; 88: 4533-4539. Go to original source... Go to PubMed...
  14. Grossrubatscher E, Dalino P, Vignati F, Gambacorta M, Pugliese R, Boniardi M, Rossetti O, Marocchi A, Bertuzzi M, Loli P. The role of chromogranin A in the management of patients with phaeochromocytoma. Clin Endocrinol (Oxf) 2006; 65: 287-293. Go to original source... Go to PubMed...
  15. Bravo EL. Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma, Endocr Rev 1994; 15: 356-368. Go to original source... Go to PubMed...
  16. Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 2007; 356: 601-610 Go to original source... Go to PubMed...
  17. Conzo G, Musella M, Corcione F, De Palma M, Ferraro F, Palazzo A, Napolitano S, Milone M, Pasquali D, Sinisi AA, Colantuoni V, Santini L. Laparoscopic adrenalectomy, a safe procedure for pheochromocytoma. A retrospective review of clinical series. Int J Surg 2013; 11: 152-156. Go to original source... Go to PubMed...
  18. Zografos GN, Vasiliadis G, Farfaras AN, Aggeli C, Digalakis M. Laparoscopic Surgery for Malignant Adrenal Tumors. JSLS 2009; 13: 196-202. Go to PubMed...
  19. Barski D. Management and follow up of extra-adrenal phaeochromocytoma. Cent European J Urol 2014; 67: 156-161. Go to original source... Go to PubMed...
  20. Johnston PC, Mullan KR, Atkinson AB, Eatock PC, Wallace H, Gray M, Hunter SJ. Recurrence of Phaeochromocytoma and Abdominal Paraganglioma After Initial Surgical Intervention. Ulster Med J 2015; 84: 102-106.




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.